Skip to main content

10-25-2022 | Devices and technology | News

News in brief

Smartphone-delivered CBT improves glycemic control in people with type 2 diabetes

Author: Alba Ruzafa


medwireNews: Findings from a randomized controlled trial published in Diabetes Care suggest that for people with type 2 diabetes, the delivery of cognitive behavioral therapy (CBT) via a digital therapeutic app, on top of standard of care, may reduce glycated hemoglobin (HbA1c).

The study included 669 adults (58% White, 28% Black, 16% Latino) aged an average of 58 years with type 2 diabetes and glycated hemoglobin (HbA1c) levels of 7.0 to less than 11.0% (53 to <97 mmol/mol) who were randomly assigned to receive access to a digital therapeutic app delivering CBT (BT-001) or a control app, both on top of standard care.

The researchers observed that people in the BT-001 group had significantly lower HbA1c than those in the control group after 90 days of using the app. In the BT-001 arm, HbA1c decreased by 0.28% from 8.2% (66 mmol/mol) at baseline, compared with an increase of 0.11% from 8.1% (65 mmol/mol) in the control group. This resulted in a between-group difference of 0.39% at day 90.

“The magnitude of HbA1c reduction in the BT-001 group increased in parallel with exposure to the therapy, as indicated by the number of modules completed,” write Judith Hsia (CPC Clinical Research, Aurora, Colorado, USA) and co-authors. They say that this “supports the importance of engagement, consistent with in-person CBT and behavioral interventions in general.”

There were no adverse events attributed to the app use and no adverse device effects were observed.

“Delivery of a cognitive behavioral intervention via smartphone app can provide a scalable option for improving glycemic control,” concludes the team.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

Diabetes Care 2022; doi:10.2337/dc22-1099


Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »